DDJ Patient Article · March 2026 · Explained clearly
How Much Does a History of Periodontitis Increase the Risk for Peri-Implantitis and Implant Loss, and What Does This Mean for Patient Selection?
Explained clearly based on current scientific evidence. This article helps you make informed decisions together with your dentist.
This topic concerns the expected course of a condition or situation and what can be derived from it for your own care.
In Brief
The most important findings at a glance:
- The results are mixed — there are both positive and critical findings.
- The scientific basis is solid, but not all questions have been definitively answered.
- Patients with treated gum disease (periodontitis) have an elevated but not prohibitive risk.
- It is not the gum disease (periodontitis) diagnosis alone that determines implant risk, but whether it is controlled and whether the patient cooperates.
Why is this topic important for you?
You may have heard that there are different opinions on this topic. This is because science is often more complex than a simple yes-or-no answer might suggest. In this article, we explain what current research actually shows — without technical jargon and without omitting important details.
A history of gum disease (periodontitis) is not an automatic exclusion criterion, but neither is it an irrelevant finding. The question is how large the actual risk really is.
Why is this important for you? Because as a patient, you can make better decisions when you understand the background. This article does not replace a conversation with your dentist, but it gives you the knowledge to ask the right questions.
In research, the key questions center on the following areas: quantification of increased risk, treated vs. untreated periodontitis, consequences for informed consent. For each of these areas, we explain below what the studies say and what it means for your daily life.
What does "quantification of increased risk" mean for me as a patient?
One of the most common questions patients ask on this topic concerns the quantification of increased risk. The answer is not as simple as one might hope — but research now provides clear guidance.
The most robust quantitative scientific evidence comes from the systematic review by Annunziata et al. (2025), which included only prospective long-term observational studies with a minimum follow-up of 36 months. From 13,761 initial records, 14 studies (17 articles) were included, with eight studies showing low and six showing moderate risk of bias according to the Newcastle-Ottawa Scale. The pooled meta-analysis showed that patients with a history of periodontitis (HP) had a significantly elevated hazard ratio for implant loss of 1.75 compared to periodontally healthy patients (NHP).
Particularly informative are the data on marginal bone loss: HP patients showed a mean bone loss 0.41 mm higher than NHP. For peri-implantitis, the odds ratio was 3.24, while no significant group difference was found for peri-implant mucositis. This distinction is clinically relevant: the risk primarily concerns the severe, bone-destructive form of the disease, not mild soft tissue inflammation.
Ravidà et al. (2024) add a cost perspective. In their retrospective analysis of 399 adults with more than 10 years of follow-up, periodontal therapy was overall cost-effective in terms of avoiding tooth extractions and implant replacement. However, heavy current smoking completely eliminated this cost-effectiveness. Former smokers with Grade C periodontitis benefited most from periodontal therapy, while smoking reduced cost-effectiveness in a dose-dependent manner.
The meta-analysis by Monje et al. (2014) focused specifically on generalized aggressive periodontitis (GAgP) and included six non-randomized prospective clinical studies. Survival rates ranged from 83.3 to 100% for GAgP, 96.4 to 100% for chronic periodontitis, and 96.9 to 100% for healthy patients over a mean period of 48 to 72 months. Although the overall risk ratio for survival was not significant (RR 0.96; 95% CI: 0.91–1.01; p = 0.14), the failure rate analysis showed a fourfold increased failure rate for GAgP compared to healthy patients (RR 4.0) and compared to chronic periodontitis (RR 3.97). Marginal bone loss was on average 0.28 mm higher in GAgP than in healthy patients and 0.43 mm higher than in chronic periodontitis.
From a methodological standpoint, it should be noted that the included studies vary considerably in study design, follow-up duration, and population selection. This heterogeneity limits the comparability of results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different study types.
For applicability to the German-language healthcare context, it is additionally relevant that a significant proportion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structures, treatment culture, and patient access may influence effect sizes without invalidating the overall conclusion.
In clinical practice, a hazard ratio of 1.75 for implant loss means that the risk is relevant but not prohibitively elevated. With a baseline implant loss rate of approximately 2 to 4% over 10 years in periodontally healthy populations, this rate in individuals with a periodontitis history rises to an estimated 3.5 to 7%, which represents an acceptable prognosis for the majority of patients, provided that periodontal status is controlled.
The 6-fold increased risk in Grade C periodontitis (HR 6.16), however, marks a clinically relevant risk threshold that must be explicitly addressed in patient selection and counseling. These patients require more intensive follow-up care and transparent communication about their limited prognosis.
In everyday practice, this means: the scientific evidence does not provide a one-size-fits-all answer, but rather a framework for individualized decisions. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be incorporated into the decision.
What does this mean for you? Patients with treated gum disease (periodontitis) have an elevated but not prohibitive risk.
What does this mean for your next dental visit? The research findings help you better understand your dentist's recommendations and ask targeted questions when something is unclear.
Science has investigated this topic intensively in recent years. Several scientific studies contribute to the current assessment. It is important to understand: not every study carries the same weight. Large, well-controlled studies with many participants provide more reliable results than small observational studies. The overall picture from these various studies is what we present to you here.
💡 What does this mean for you?
Patients with treated gum disease (periodontitis) have an elevated but not prohibitive risk. Talk to your dentist at your next visit about what this means specifically for your situation.
What is better: treated or untreated periodontitis?
When it comes to treated vs. untreated periodontitis, the research is clearer than many would think. Here you will find out what current studies actually show.
The clinically decisive difference lies not in the diagnosis of gum disease (periodontitis) itself, but in the current periodontal status at the time of implant placement. Annunziata et al. (2025) show in subgroup analyses that patients with Stage III to IV (severe) periodontitis have a higher risk of implant loss than patients with milder disease, and that implants with rough surfaces in HP patients carry an additionally elevated loss risk.
Monje et al. (2014) emphasize that residual periodontal pockets serve as an infectious reservoir for implants and that periodontal pathogens remain detectable up to one year after extraction of periodontally compromised teeth. The ecological conditions of the oral cavity directly influence biofilm formation on implants, which explains the mechanistic link between active periodontitis and peri-implantitis risk.
The cost analysis by Ravidà et al. (2024) indirectly confirms the value of periodontal pre-treatment: patients who had the lowest annual periodontal therapy costs had the highest costs for tooth extractions and implant replacement, suggesting undertreatment. Conversely, invested periodontal therapy was cost-effective in terms of avoiding implant need among non-smokers and former smokers.
Bezerra et al. (2022) investigated in a meta-analysis the role of pro-inflammatory gene variants in peri-implantitis and included studies analyzing the association between genetic polymorphisms (particularly IL-1 and TNF-alpha variants) and peri-implant disease. Although a trend toward increased peri-implantitis risk with certain polymorphisms was observed, the evidence was heterogeneous and insufficient to recommend genetic testing as a clinical selection criterion.
From a methodological standpoint, it should be noted that the included studies vary considerably in study design, follow-up duration, and population selection. This heterogeneity limits the comparability of results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different study types.
For applicability to the German-language healthcare context, it is additionally relevant that a significant proportion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structures, treatment culture, and patient access may influence effect sizes without invalidating the overall conclusion.
For clinical practice, this evidence means that the implant indication in individuals with periodontal disease depends not on the diagnosis alone but on the current control status. Prior to implant planning, the periodontal examination must be complete, any active periodontitis must be treated, and a stable condition documented for at least three to six months.
Modifiable risk factors such as smoking and oral hygiene compliance must be addressed before implant placement, as they influence prognosis more strongly than the historical diagnosis. Smoking cessation should be considered an integral part of implant planning in individuals with periodontal disease.
In everyday practice, this means: the scientific evidence does not provide a one-size-fits-all answer, but rather a framework for individualized decisions. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be incorporated into the decision.
What does this mean for you? Successfully treated gum disease (periodontitis) significantly reduces implant risk compared to uncontrolled disease.
What does this mean for your next dental visit? The research findings help you better understand your dentist's recommendations and ask targeted questions when something is unclear.
How do scientists arrive at these conclusions? They do not evaluate just one single study but look at many investigations simultaneously. This allows them to determine whether a result was coincidental or whether it is repeatedly confirmed. In this case, the findings are based on 5 scientific studies from different countries and research groups.
💡 What does this mean for you?
Successfully treated gum disease (periodontitis) significantly reduces implant risk compared to uncontrolled disease. Talk to your dentist at your next visit about what this means specifically for your situation.
What does "consequences for informed consent" mean for me as a patient?
A point that often causes uncertainty is the consequences for informed consent. However, science has made important progress in recent years.
The quantified risk increases enable differentiated patient counseling. Annunziata et al. (2025) provide the basis for evidence-based risk stratification: in chronic periodontitis with controlled status and good compliance, the implant loss risk is moderately above that of periodontally healthy patients (HR 1.75). In formerly aggressive or Grade C periodontitis, the risk increases sixfold, requiring intensive follow-up care and an explicitly more restrictive indication.
Monje et al. (2014) quantify marginal bone loss as an additional prognostic parameter: the weighted mean difference was -0.28 mm for GAgP versus healthy and -0.43 mm for GAgP versus chronic periodontitis over a mean period of 30 months. This accelerated bone loss is an early indicator of implant risk and should be closely monitored at recall visits.
For informed consent, it is relevant that the differences are real but not dramatic, as long as periodontitis is controlled. Annunziata et al. (2025) found no significant difference in peri-implant mucositis between HP and NHP patients, suggesting that early inflammatory signs occur equally and that it is the transition to destructive peri-implantitis that marks the risk differential.
Smoking considerably potentiates the periodontitis-associated risk. Ravidà et al. (2024) show in a dose-dependent manner that heavy current smokers completely lose the cost-effectiveness of periodontal therapy. For implant counseling, this means that the combination of a periodontitis history and active smoking represents a particularly critical risk constellation.
From a methodological standpoint, it should be noted that the included studies vary considerably in study design, follow-up duration, and population selection. This heterogeneity limits the comparability of results and explains why pooled effect estimates must be interpreted with caution. Nevertheless, the direction of the effect is consistent across different study types.
For applicability to the German-language healthcare context, it is additionally relevant that a significant proportion of the scientific evidence comes from Anglo-American or Scandinavian healthcare systems. Differences in reimbursement structures, treatment culture, and patient access may influence effect sizes without invalidating the overall conclusion.
Informed consent should transparently address three risk levels: controlled chronic periodontitis (moderately elevated risk), severe or rapidly progressing periodontitis (significantly elevated risk), and active or uncontrolled periodontitis (implantation not indicated until stabilization). Modifiable factors such as smoking cessation and compliance should be communicated as prognostically favorable.
Follow-up care in patients with periodontal disease and implants must be more frequent than in periodontally healthy patients. A recall interval of three to six months with systematic recording of probing depths, bleeding on probing, and radiographic bone levels is indicated.
In everyday practice, this means: the scientific evidence does not provide a one-size-fits-all answer, but rather a framework for individualized decisions. Patient-specific factors such as general health, compliance, individual risk profiles, and treatment preferences must be incorporated into the decision.
What does this mean for you? Informed consent requires a quantified risk statement.
What does this mean for your next dental visit? The research findings help you better understand your dentist's recommendations and ask targeted questions when something is unclear.
What makes these results reliable? In medical research, the more independent studies arrive at the same result, the more certain the conclusion. The type of study and the number of participants also play an important role. Large controlled studies with many participants provide more reliable results than small surveys.
💡 What does this mean for you?
Informed consent requires a quantified risk statement. Talk to your dentist at your next visit about what this means specifically for your situation.
Frequently Asked Questions
Here we answer the questions patients most frequently ask on this topic:
❓ What does "quantification of increased risk" mean for me as a patient?
Patients with treated gum disease (periodontitis) have an elevated but not prohibitive risk.
❓ What is better: treated or untreated periodontitis?
Successfully treated gum disease (periodontitis) significantly reduces implant risk compared to uncontrolled disease.
❓ What does "consequences for informed consent" mean for me as a patient?
Informed consent requires a quantified risk statement.
❓ How reliable are the results?
The scientific basis is solid, but not all questions have been definitively answered.
❓ Should I change my behavior based on this information?
Talk to your dentist before making any changes. This article informs you about the current state of research, but every situation is individual. Your dentist knows your personal health situation best.
❓ Where can I find more information?
The detailed professional version of this article with all study details can be found on Daily Dental Journal. For personal advice, please consult your dentist.
❓ What is the most important message of this article?
A history of gum disease (periodontitis) increases the risk but does not exclude implants.
❓ Why are there different opinions on this topic?
The conflict lies between prognostic pessimism and the clinical reality that many people with periodontal disease are successfully treated with implants.
🦷 When should you see your dentist?
Schedule an appointment with your dentist if:
- You are unsure whether a recommended treatment is appropriate for you
- You have symptoms or notice changes
- You would like to seek a second opinion
- You have questions about the topics described in this article
- Your last dental visit was more than a year ago
Important: This article does not replace a dental visit. It helps you go into the conversation informed.
What you can do yourself
Here are concrete steps you as a patient can take:
The Most Important Point in One Sentence
It is not the gum disease (periodontitis) diagnosis alone that determines implant risk, but whether it is controlled and whether the patient cooperates.
Note on Sources
This article is based on current scientific evidence and the DDJ editorial assessment. All statements are supported by studies and have been prepared in a way that is understandable for patients.
The content has been prepared for patients by the DDJ editorial team. Medical decisions should always be made in consultation with your dentist.
Date: March 2026 · Language: English · Audience: Patients and interested laypeople